Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
This strategic decision will unlock significant value for our scientific and industrial products business
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
Subscribe To Our Newsletter & Stay Updated
